Intelligence Driven Advisers LLC Cuts Position in Eli Lilly and Company (NYSE:LLY)

Intelligence Driven Advisers LLC lessened its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 37.8% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,102 shares of the company's stock after selling 669 shares during the quarter. Intelligence Driven Advisers LLC's holdings in Eli Lilly and Company were worth $910,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. WestEnd Advisors LLC increased its position in Eli Lilly and Company by 210.0% in the first quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock worth $26,000 after purchasing an additional 21 shares during the last quarter. Citizens National Bank Trust Department lifted its position in Eli Lilly and Company by 180.0% during the first quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock valued at $35,000 after purchasing an additional 27 shares during the last quarter. Mascagni Wealth Management Inc. purchased a new position in shares of Eli Lilly and Company in the 4th quarter worth $43,000. Prudent Man Investment Management Inc. purchased a new position in shares of Eli Lilly and Company in the 4th quarter worth $48,000. Finally, Highline Wealth Partners LLC increased its holdings in shares of Eli Lilly and Company by 53.3% in the 1st quarter. Highline Wealth Partners LLC now owns 69 shares of the company's stock worth $57,000 after buying an additional 24 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Trading Down 0.3%

Shares of NYSE LLY traded down $2.66 during trading hours on Thursday, reaching $776.62. The stock had a trading volume of 666,685 shares, compared to its average volume of 3,659,847. Eli Lilly and Company has a 52-week low of $677.09 and a 52-week high of $972.53. The firm has a market cap of $736.04 billion, a price-to-earnings ratio of 63.22, a P/E/G ratio of 1.13 and a beta of 0.40. The business's fifty day moving average price is $777.35 and its two-hundred day moving average price is $799.71. The company has a current ratio of 1.37, a quick ratio of 1.06 and a debt-to-equity ratio of 2.18.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing the consensus estimate of $4.64 by ($1.30). The firm had revenue of $12.73 billion during the quarter, compared to analysts' expectations of $12.77 billion. Eli Lilly and Company had a return on equity of 85.51% and a net margin of 22.67%. Eli Lilly and Company's quarterly revenue was up 45.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.58 earnings per share. Analysts expect that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be given a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a yield of 0.77%. The ex-dividend date of this dividend is Friday, August 15th. Eli Lilly and Company's dividend payout ratio (DPR) is 48.82%.

Analysts Set New Price Targets

A number of research analysts recently commented on the stock. Cantor Fitzgerald assumed coverage on shares of Eli Lilly and Company in a report on Tuesday, April 22nd. They issued an "overweight" rating and a $975.00 price target for the company. HSBC lowered Eli Lilly and Company from a "buy" rating to a "reduce" rating and lowered their price objective for the company from $1,150.00 to $700.00 in a research note on Monday, April 28th. UBS Group cut their target price on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating on the stock in a research report on Friday, May 2nd. Wells Fargo & Company restated an "overweight" rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. Finally, Erste Group Bank lowered shares of Eli Lilly and Company from a "buy" rating to a "hold" rating in a research note on Thursday, June 5th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and sixteen have given a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $1,011.61.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.